UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

JAMA : the journal of the American Medical Association, 2003-06, Vol.289 (21), p.2801

2003

Volltextzugriff (PDF)

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

HIV medicine, 2014-08, Vol.15 (7), p.431-441

2014

Volltextzugriff (PDF)

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Journal of acquired immune deficiency syndromes (1999), 2005-12, Vol.40 (4), p.404-412

2005

Volltextzugriff (PDF)

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

The Lancet infectious diseases, 2014-07, Vol.14 (7), p.572-580

2014

Volltextzugriff (PDF)

Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC)

HIV medicine, 2021-09, Vol.22 (8), p.759-769

2021

Volltextzugriff (PDF)

Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects

AIDS (London), 1998-09, Vol.12 (13), p.1653-1659

1998

Volltextzugriff (PDF)

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

Journal of acquired immune deficiency syndromes (1999), 2009-04, Vol.50 (4), p.367-374

2009

Volltextzugriff (PDF)

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

The lancet HIV, 2018-01, Vol.5 (1), p.e23-e34

2018

Volltextzugriff (PDF)

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial

Clinical infectious diseases, 2006-11, Vol.43 (10), p.1337-1346

2006

Volltextzugriff (PDF)

High prevalence of unintended pregnancies in HIV‐positive women of reproductive age in Ontario, Canada: a retrospective study

HIV medicine, 2012-02, Vol.13 (2), p.107-117

2012

Volltextzugriff (PDF)

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

AIDS (London), 2009-11, Vol.23 (17), p.2289-2300

2009

Volltextzugriff (PDF)

Fragility fractures and bone mineral density in HIV positive women : a case-control population-based study

Osteoporosis international, 2007-10, Vol.18 (10), p.1345-1353

2007

Volltextzugriff (PDF)

Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study

International journal of epidemiology, 2010-10, Vol.39 (5), p.1162-1169

2010

Volltextzugriff (PDF)

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

Pediatrics (Evanston), 2009-05, Vol.123 (5), p.1360-1368

2009

Volltextzugriff (PDF)

Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis

The Journal of infectious diseases, 2012-04, Vol.205 (8), p.1230-1238

2012

Volltextzugriff (PDF)

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

The lancet HIV, 2017-11, Vol.4 (11), p.e486-e494

2017

Volltextzugriff (PDF)

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

The Journal of infectious diseases, 2020-07, Vol.222 (Supplement_1), p.S8-S19

2020

Volltextzugriff (PDF)

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

AIDS (London), 2010-08, Vol.24 (13), p.2019-2027

2010

Volltextzugriff (PDF)

Active surveillance for candidemia, Australia

Emerging infectious diseases, 2006-10, Vol.12 (10), p.1508-1516

2006

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

The lancet HIV, 2020-01, Vol.7 (1), p.e16-e26

2020

Volltextzugriff (PDF)

Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management

Clinical microbiology and infection, 2009-07, Vol.15 (7), p.662-669

2009

Volltextzugriff (PDF)

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral‐treated HIV/hepatitis C virus‐coinfected patients

HIV medicine, 2015-01, Vol.16 (1), p.24-31

2015

Volltextzugriff (PDF)

Opioid use and risk of liver fibrosis in HIV/hepatitis C virus‐coinfected patients in Canada

HIV medicine, 2016-01, Vol.17 (1), p.36-45

2016

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaInfectious Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(73)
Humans
(69)
Adult
(60)
Female
(55)
Male
(51)
Biological And Medical Sciences
(46)
Medical Sciences
(46)
Middle Aged
(45)
Hiv
(37)
Hiv Infections - Drug Therapy
(37)
Immunology
(34)
Human Immunodeficiency Virus
(32)
Viral Diseases
(26)
Human Viral Diseases
(25)
Viral Load
(24)
Microbiology
(23)
Virology
(23)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(21)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC)

Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality

High prevalence of unintended pregnancies in HIV‐positive women of reproductive age in Ontario, Canada: a retrospective study

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

Fragility fractures and bone mineral density in HIV positive women : a case-control population-based study

Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

Active surveillance for candidemia, Australia

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management

HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral‐treated HIV/hepatitis C virus‐coinfected patients

Opioid use and risk of liver fibrosis in HIV/hepatitis C virus‐coinfected patients in Canada

Aktive Filter

Suchergebnisse filtern